SweetSpot - L'Effetto degli Edulcoranti Non Nutritivi sulla Salute
SweetSpot - Effetto dei dolcificanti non nutritivi sulla regolazione del glucosio, sul microbioma intestinale e sulla secrezione di ormoni intestinali in adulti sani: uno studio di intervento cross-over completamente controllato
The aim of the study is to investigate the effect of non-nutritive sweeteners on glucose regulation. Secondary objectives are to investigate the effect of NNS on gut microbiome, gut hormone secretion, sweet taste sensitivity and preference, and the excretion of NNS in urine.
Panoramica dello studio
Stato
Stato
Condizioni
Condizioni
Intervento / Trattamento
Intervento / Trattamento
Descrizione dettagliata
Sugar intake has increased over the years, simultaneously with the prevalence of overweight and obesity. To decrease sugar intake, consumption of non-nutritive sweeteners (NNS) has increased and opinions on its use remain divided. A fully controlled dietary intervention using a NNS mixture and dose that is similar to real-life intake, is therefore necessary to advance our understanding of the potential effects of NNS on glucose regulation, gut microbiome, and gut hormone secretion under real-life conditions.
The aim of this study is to investigate the effect of non-nutritive sweeteners on glucose regulation. Secondary objectives are to investigate the effect of NNS on gut microbiome, gut hormone secretion, sweet taste sensitivity and preference, and the excretion of NNS in urine.
To do this, a single blind, fully controlled dietary intervention with a cross-over design will be performed. The study will consist of 2x8 weeks of intervention, with a washout of > 6 weeks in between. The study population will be 60 healthy adults aged 45-79, with a BMI between 20-35 kg/m2.
The study will consist of a fully controlled diet of two 8-week intervention periods (2 weeks run-in + 6 weeks intervention). The diets differ in the presence of non-nutritive sweeteners (NNS): NNS-diet versus non-NNS diet, where additional NNS are added to the NNS-diet.
The primary outcome measure will be the within person difference in blood glucose incremental area under the curve following a 75 g glucose tolerance test between the NNS diet and the non-NNS diet. Secondary outcome measures are the effect of NNS on Matsuda index, insulin response, blood lipid profile, and gut hormone secretion will be determined. The effect of NNS on small- and large intestinal microbiome will be investigated by a change in composition, functionality, and short chain fatty acid content. The effect of NNS on sweet taste sensitivity, preference, and liking will be investigated, as well as the excretion of NNS in urine and saliva.
The total time invested by participants is around 85 hours. Participants are restricted for 16 weeks in their eating habits, since they follow a fully controlled diet prepared by the research facility. Participants will visit the research facility in total 38 times. In total, ~ 603 mL of blood will be drawn by experienced nurses over the entire RCT (>6 month period). During DEXA scans, participants will receive a total of about 0.006 mSv of radiation.
Invasive measurements that participants can experience as burden are collection of faecal and urine samples, and finding back the Simba capsules in the stool. Non-invasive measurements for participants are wearing the CGM, wearing the ActiGraph, consuming the blue cakes, and performing sensory tests.
Tipo di studio
Tipo di studio
Iscrizione (Stimato)
Iscrizione
Fase
Fase
- Non applicabile
Contatti e Sedi
Luoghi di studio
-
-
Gelderland
-
Wageningen, Gelderland, Olanda, 6708WG
- Wageningen University & Research
-
-
Criteri di partecipazione
Criteri di ammissibilità
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
Inclusion Criteria:
- Age 45-79 years;
- BMI of 20-35 kg/m2;
- Having veins suitable for placement of a venflon catheter.
Exclusion Criteria:
- Diseases or prior surgeries affecting the stomach, liver, kidneys or intestines (allowed i.e. appendectomy);
- Cardiovascular diseases (e.g. heart failure) or cancer (e.g. non-invasive skin cancer allowed);
- Diagnosed with type 1 or type 2 diabetes;
- Drug treated thyroid diseases (well substituted hypothyroidism is allowed for inclusion);
- HbA1c level >6.5% (>48 mmol/mol), as measured during the screening visit;
- Anaemia defined as Hb concentrations <8.5 mmol/L for men and <7.5 mmol/L for women via finger prick;
- Regular use of/receiving medication interfering with research outcomes (as judged by research physician), such as use of glucose lowering drugs, insulin, or use of medication that impacts the gastro-intestinal system;
- Use of antibiotics over the last 3 months before study start;
- Donated blood within 2 months prior to the screening;
- Food allergies, intolerances (including lactose/gluten intolerance) for products used in the study design and/or dietary restrictions interfering with the study (including special diets and eating disorders);
- Followed a diet that can interfere with the study outcomes within 1 month prior to the screening (e.g. ketogenic, sugar free, carbohydrate free);
- Not willing to eat all products in the study diet, including eggs and dairy. Vegetarian is possible;
- Not willing to consume non-nutritive sweeteners;
- Not willing to quit the use of supplements that can interfere with the study outcomes (e.g. pre- or probiotics).
- Intention to change the intensity of exercise during the study period or planning to join a intensive sport event (e.g. marathon or triathlon);
- Intention to lose or gain weight;
- Working night shifts regularly;
- Smoking regularly
- Use of soft and/or hard drugs (cannabis included);
- Abuse of alcohol (defined as >14 glasses (women) or >21 glasses (men) of alcoholic beverages per week);
- Being pregnant or lactating or planning to become pregnant;
- Inability to understand study information and/or communicate with staff;
- Participation in another study that involves an intervention within two months prior to the intervention;
- Working or doing a thesis/internship at the division of Human Nutrition & Health, or the Food, Health & Consumer Research group of Wageningen Food & Biobased Research.
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Altro
- Assegnazione: Randomizzato
- Modello interventistico: Assegnazione incrociata
- Mascheramento: Separare
Numero di armi
Armi e interventi
Gruppo di partecipanti / ArmGruppo di partecipanti / Arm |
Intervento / TrattamentoIntervento / Trattamento |
|---|---|
|
Altro: NNS / no-NNS
In this arm, participants will first receive the NNS diet, and the no-NNS diet in the second study period. |
Fully controlled diet with added mixture of non-nutritive sweeteners. The mixture consist of 6 different non-nutritive sweeteners: acesulfame-K, aspartame, cyclamate, saccharin, sucralose, and rebaudioside A (stevia). Fully controlled diet without any non-nutritive sweeteners added. |
|
Altro: No-NNS / NNS
In this arm, participants will first receive the no-NNS diet, and the NNS diet in the second study period. |
Fully controlled diet with added mixture of non-nutritive sweeteners. The mixture consist of 6 different non-nutritive sweeteners: acesulfame-K, aspartame, cyclamate, saccharin, sucralose, and rebaudioside A (stevia). Fully controlled diet without any non-nutritive sweeteners added. |
Cosa sta misurando lo studio?
Misure di risultato primarie
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Difference in change in 2h iAUC glucose after 6 weeks between the intervention and the control.
Lasso di tempo: Week 2 and week 8 in both intervention periods (4 times in total)
|
The primary outcome measure is the difference in change in iAUC of blood glucose levels following a 2-hour oral glucose tolerance test (OGTT) after six weeks between the intervention period and the control period. |
Week 2 and week 8 in both intervention periods (4 times in total)
|
Misure di risultato secondarie
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Matsuda index
Lasso di tempo: Week 2 and week 8 in both intervention periods (4 times in total)
|
Matsuda index after an OGTT |
Week 2 and week 8 in both intervention periods (4 times in total)
|
|
Fasting blood glucose
Lasso di tempo: Baseline & 2 times per intervention period (week 2 and week 8). 5 times in total.
|
Fasting blood glucose |
Baseline & 2 times per intervention period (week 2 and week 8). 5 times in total.
|
|
Fasting blood insulin
Lasso di tempo: Baseline & 2 times per intervention period (week 2 and week 8). 5 times in total.
|
Fasting blood insulin |
Baseline & 2 times per intervention period (week 2 and week 8). 5 times in total.
|
|
Postprandial insulin response
Lasso di tempo: Week 2 and 8 in both intervention periods (4 times in total).
|
2-hour iAUC blood insulin during OGTT |
Week 2 and 8 in both intervention periods (4 times in total).
|
|
Postprandial glucose response after a breakfast
Lasso di tempo: Week 7 in both study periods (2 times in total)
|
Postprandial blood glucose responses (PPGR) following specific meals measured by CGM. |
Week 7 in both study periods (2 times in total)
|
|
Blood lipid profile
Lasso di tempo: Baseline & 2 times per intervention period (week 2 and week 8). 5 times in total.
|
All circulating blood lipids, including all cholesterol types, triglycerides, and free fatty acids (FFAs). |
Baseline & 2 times per intervention period (week 2 and week 8). 5 times in total.
|
|
Gut microbiota composition
Lasso di tempo: Average of three samples per timepoint. Measured at baseline & 2 times per intervention period (week 2 and week 8). 15 samples over 5 timepoints in total.
|
Microbiota composition in faeces |
Average of three samples per timepoint. Measured at baseline & 2 times per intervention period (week 2 and week 8). 15 samples over 5 timepoints in total.
|
|
Gut microbiota function
Lasso di tempo: Average of three samples per timepoint. Measured at baseline & 2 times per intervention period (week 2 and week 8). 15 samples over 5 timepoints in total.
|
Microbiota functionality measured in faeces |
Average of three samples per timepoint. Measured at baseline & 2 times per intervention period (week 2 and week 8). 15 samples over 5 timepoints in total.
|
|
Microbial metabolites
Lasso di tempo: Average of three samples per timepoint. Measured at baseline & 2 times per intervention period (week 2 and week 8). 15 samples over 5 timepoints in total.
|
Microbial metabolites measured in faeces |
Average of three samples per timepoint. Measured at baseline & 2 times per intervention period (week 2 and week 8). 15 samples over 5 timepoints in total.
|
|
Small intestinal microbiota composition
Lasso di tempo: Week 7 of both intervention periods (2 times in total).
|
Microbiota composition of the small intestine measured with Simba Capsules |
Week 7 of both intervention periods (2 times in total).
|
|
Gastro-intestinal transit time
Lasso di tempo: Baseline & week 7 of both intervention periods (3 times in total).
|
Gastro-intestinal transit time measured with blue muffins. |
Baseline & week 7 of both intervention periods (3 times in total).
|
|
Oral microbiome composition & function
Lasso di tempo: Baseline & 2 times per intervention period (week 2 and week 8). 5 times in total.
|
Oral microbiome composition & function measured in saliva |
Baseline & 2 times per intervention period (week 2 and week 8). 5 times in total.
|
|
Postprandial GLP-1 secretion
Lasso di tempo: Week 2 and 8 of both intervention periods (4 times in total).
|
3-hour AUC of GLP-1 during an OGTT. |
Week 2 and 8 of both intervention periods (4 times in total).
|
|
Postprandial GIP secretion
Lasso di tempo: Week 2 and 8 of both intervention periods (4 times in total).
|
3-hour AUC of GIP during an OGTT. |
Week 2 and 8 of both intervention periods (4 times in total).
|
|
Sweetness-liker phenotype
Lasso di tempo: Baseline & 2 times per intervention period (week 2 and week 8). 5 times in total.
|
Sweetness-liker phenotype, with the sweetness liker test. |
Baseline & 2 times per intervention period (week 2 and week 8). 5 times in total.
|
|
Sweetness preference & liking
Lasso di tempo: Baseline & 2 times per intervention period (week 2 and week 8). 5 times in total.
|
Sweetness preference & liking measured on a rank-rating scale. Preference will be determined using the categorical values from the rank-rating scale (1-5), and liking will be determined using the continuous values from the rank-rating scale (0-100). |
Baseline & 2 times per intervention period (week 2 and week 8). 5 times in total.
|
|
Sweet taste sensitivity
Lasso di tempo: Baseline & 2 times per intervention period (week 2 and week 8). 5 times in total.
|
Sweet taste sensitivity measured on a 100mm Visual Analogue Scale. A higher score for all solutions indicates a higher sweet taste sensitivity. |
Baseline & 2 times per intervention period (week 2 and week 8). 5 times in total.
|
|
Excretion of NNS in urine
Lasso di tempo: Baseline, week 2 and week 8 in intervention period 1, and every two weeks in intervention period 2 (7 times in total).
|
Excretion of NNS in urine |
Baseline, week 2 and week 8 in intervention period 1, and every two weeks in intervention period 2 (7 times in total).
|
|
Excretion of NNS in saliva
Lasso di tempo: Baseline & 2 times per intervention period (week 2 and week 8). 5 times in total.
|
Excretion of NNS in saliva |
Baseline & 2 times per intervention period (week 2 and week 8). 5 times in total.
|
Altre misure di risultato
Altre misure di risultato
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Anthropometrics
Lasso di tempo: Baseline
|
Measured as weight (kg), height (m), waist circumference (cm), and hip circumference (cm). Weight and height will be combined to report BMI in kg/m^2. |
Baseline
|
|
Body composition
Lasso di tempo: Baseline & week 8 of both intervention periods (3 times in total).
|
Body composition as measured by DEXA (Dual Energy X-ray Absorptiometry). |
Baseline & week 8 of both intervention periods (3 times in total).
|
|
Habitual food intake
Lasso di tempo: Baseline
|
Habitual dietary intake assessment with a food frequency questionnaire (FFQ). |
Baseline
|
|
Physical activity level
Lasso di tempo: Baseline.
|
Physical activity level by the Short Questionnaire to Assess Health-enhancing physical activity (SQUASH). |
Baseline.
|
|
Habitual NNS consumption
Lasso di tempo: Baseline
|
Habitual NNS consumption by questionnaire |
Baseline
|
|
Gastro-intestinal symptoms
Lasso di tempo: Once during the characterisation period (1 week), and every week during the first intervention period (8 weeks) and every week during the second intervention period (8 weeks). In total up to 17 weeks.
|
Gastro-intestinal symptoms by GSRS questionnaire. |
Once during the characterisation period (1 week), and every week during the first intervention period (8 weeks) and every week during the second intervention period (8 weeks). In total up to 17 weeks.
|
|
Satiety
Lasso di tempo: Once during the characterisation period (1 week), and every week during the first intervention period (8 weeks) and every week during the second intervention period (8 weeks). In total up to 17 weeks.
|
Satiety questionnaire, adapted from the Control of Eating Questionnaire. |
Once during the characterisation period (1 week), and every week during the first intervention period (8 weeks) and every week during the second intervention period (8 weeks). In total up to 17 weeks.
|
|
Genetic variation
Lasso di tempo: Baseline
|
Single Nucleotide Polymorphisms (SNPs) in genes relevant collected using buffycoat. |
Baseline
|
|
Taste function
Lasso di tempo: Baseline
|
Measure the ability to recognize the basic tastes in different concentrations, assessed with validated Taste Strips. |
Baseline
|
Collaboratori e investigatori
Sponsor
Sponsor
Collaboratori
Collaboratori
Studiare le date dei record
Studia le date principali
Inizio studio (Effettivo)
Inizio studio
Completamento primario (Stimato)
Completamento primario
Completamento dello studio (Stimato)
Completamento dello studio
Date di iscrizione allo studio
Primo inviato
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Primo Inserito
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento pubblicato
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Parole chiave
Termini MeSH pertinenti aggiuntivi
Altri numeri di identificazione dello studio
Altri numeri di identificazione dello studio
- NL010297
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .